Thiazolidinediones and type 2 diabetes: new drugs for an old disease

Trisha M O'Moore-Sullivan and Johannes B Prins
Med J Aust 2002; 176 (8): . || doi: 10.5694/j.1326-5377.2002.tb04461.x
Published online: 15 April 2002

The recent AusDiab data show that 7.2% of Australians over 25 years of age have type 2 diabetes mellitus and a further 16.1% have impaired glucose tolerance. In fact, 20% of Australians over 65 years have type 2 diabetes and it is well known that morbidity and mortality are significantly increased in affected patients.1,2 However, there is evidence from the United Kingdom Prospective Diabetes Study (UKPDS) that good glycaemic control can improve morbidity by improving microvascular complications of type 2 diabetes, such as retinopathy, nephropathy and neuropathy3 (E2). (See Box 1 for an explanation of level-of-evidence codes.) There is a well-recognised and strong association of type 2 diabetes with obesity and the insulin resistance syndrome. "Syndrome X"5 refers to a collection of pathophysiological sequelae resulting from insulin resistance and includes type 2 diabetes, as well as hypertension, dyslipidaemia, hyperuricaemia and elevated plasminogen-activator-inhibitor-1 levels.6

  • Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD.

Competing interests:

The authors have received competitive funding for basic scientific research from Novo Nordisk and from Eli Lilly. The views expressed in this article are those of the authors and neither company has had input into the content.

  • 1. AusDiab preliminary results media release. 30 May 2000. <> (no longer available)
  • 2. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
  • 3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
  • 4. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, AusInfo, 1999.
  • 5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
  • 6. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycaemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
  • 7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
  • 8. Avandia (rosiglitazone maleate) product information. Dandenong, Victoria: SmithKline Beecham (Aust) Pty Ltd, 6 July 2000.
  • 9. Actos (pioglitazone hydrochloride) product information. West Ryde, NSW: Eli Lilly Pty Ltd Australia, 3 Jan 2001.
  • 10. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 2000; 106: 467-472.
  • 11. Spiegelman BM. PPARγ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
  • 12. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor γ have depot specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
  • 13. Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 2000; 4: 461-467.
  • 14. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
  • 15. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
  • 16. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
  • 17. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 287-294.
  • 18. Goldstein B, Salzman A. Rosiglitazone is effective in poorly controlled type 2 diabetes patients [abstract]. Diabetologia 1999; 42 Suppl 1: A229.
  • 19. Rebuck AS, Weill S, Patwardhan R. Rosiglitazone given once or twice daily is effective first-line treatment for type 2 diabetes mellitus [abstract]. Diabetologia 1999; 42 Suppl 1: A231.
  • 20. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000; 23: 1605-1611.
  • 21. Mathisen A, Geerlof J, Houser V. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl 1: A102-A103.
  • 22. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-343.
  • 23. Wolffenbuttel BHR, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
  • 24. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000; 283: 1695-1702.
  • 25. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med 2001; 111: 10-17.
  • 26. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-1409.
  • 27. Raskin P, Rendell M, Riddle M, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
  • 28. Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl 1: A110.
  • 29. Presentation to the 73rd meeting of the FDA Endocrinologic and Metabolic Drugs Advisory Committee, April 22, 1999: 25-27, 91-104. <>
  • 30. King AB. A comparison in a clinical setting of the efficacy and side-effects of three thiazolidinediones [letter]. Diabetes Care 2000; 23: 557.
  • 31. Brunzell J, Cohen BR, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl 2: A141.
  • 32. Winkler K, Friedrich I, Nauck M, et al. Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes [abstract]. Diabetes 2001; 50 Suppl 2: A147.
  • 33. Charbonnel B, Lonnqvist F, Jones NP, et al. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after one year of treatment in type 2 diabetic patients [abstract]. Diabetes 1999; 48 Suppl 1: A114.
  • 34. Gale EAM. Lessons form the glitazones: a story of drug development. Lancet 2001; 357: 1870-1875.
  • 35. Bailey CJ. The rise and fall of troglitazone. Diabet Med 2000; 17: 414.
  • 36. Lumpkin MM. Presentation to FDA Advisory Committee, May 19 2000. <>
  • 37. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121-124.
  • 38. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118-121.
  • 39. Ravinuthala RS, Nori U. Rosiglitazone toxicity [letter]. Ann Intern Med 2000; 133: 658.
  • 40. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [letter]. Ann Intern Med 2001; 135: 306.
  • 41. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Ann Rev Med 2001; 52: 239-257.
  • 42. Inglis AL, Miller AK, Thompson Culkin K, et al. Rosiglitazone, a PPAR agonist, does not alter the pharmacokinetics of oral contraceptive. Diabetes 1999; 48 Suppl 1: A103.
  • 43. Schoonjans K, Auwerx J. Thiazolidinediones; an update. Lancet 2000; 355: 1008-1010.
  • 44. National Institute for Clinical Excellence. Technology appraisal guidance 9: guidance on rosiglitazone for type 2 diabetes. <>
  • 45. National Institute for Clinical Excellence. Technology appraisal guidance 21: guidance on pioglitazone for type 2 diabetes. <>


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.